Astellas doubles down on gene therapy with $3bn Audentes deal
05-12-2019
Astellas-backed Crescendo pairs up with Zai Lab in licensing deal
31-05-2018
Astellas Pharma expands portfolio by acquiring Universal Cells
16-02-2018
Mark_Kuiken / iStockphoto.com
Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Astellas, Quethera, mergers and acquisitions, M&A, gene therapy, ocular disorders, glaucoma, pipeline
